{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:34:13Z","timestamp":1787668453149,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Open Project of Key Laboratory of Colleges and Universities in Jiangsu Province","award":["XZSYSKF2021041"],"award-info":[{"award-number":["XZSYSKF2021041"]}]},{"name":"Science and Technology Development Fund of Afliated Hospital of Xuzhou Medical University","award":["XYFM2021017"],"award-info":[{"award-number":["XYFM2021017"]}]},{"name":"Medical research project of Jiangsu Provincial Health Commission","award":["M2022118"],"award-info":[{"award-number":["M2022118"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00415-023-12036-y","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T13:01:51Z","timestamp":1696683711000},"page":"584-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report"],"prefix":"10.1007","volume":"271","author":[{"given":"Zhouao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-6994","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"key":"12036_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian D-C, Zhang C, Li Z, Zhai Y et al (2020) Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac 5:100063. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100063","journal-title":"Lancet Reg Health West Pac"},{"key":"12036_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329284","author":"V Damato","year":"2022","unstructured":"Damato V, Spagni G, Monte G, Woodhall M, Jacobson L et al (2022) Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2022-329284","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12036_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"12036_CR4","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"12036_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","volume":"267","author":"E Gomez-Figueroa","year":"2020","unstructured":"Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, Cervantes-Uribe R, Chac-Lezama G et al (2020) Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neurol 267:674\u2013678. https:\/\/doi.org\/10.1007\/s00415-019-09622-4","journal-title":"J Neurol"},{"key":"12036_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z (2022) Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 58:23\u201332. https:\/\/doi.org\/10.1358\/dot.2022.58.1.3352743","journal-title":"Drugs Today (Barc)"},{"key":"12036_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00005-021-00626-5","volume":"69","author":"E Sobieszczuk","year":"2021","unstructured":"Sobieszczuk E, Szczudlik P, Kubiszewska J, Szyluk B, Lipowska M et al (2021) Lower BAFF levels in myasthenic patients treated with glucocorticoids. Arch Immunol Ther Exp (Warsz) 69:22. https:\/\/doi.org\/10.1007\/s00005-021-00626-5","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"12036_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S et al (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"12036_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1620\/tjem.2022.J074","volume":"258","author":"X Ma","year":"2022","unstructured":"Ma X, Fu X, Cui B, Lin H (2022) Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature. Tohoku J Exp Med 258:219\u2013223. https:\/\/doi.org\/10.1620\/tjem.2022.J074","journal-title":"Tohoku J Exp Med"},{"key":"12036_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014","journal-title":"Kidney Int Rep"},{"key":"12036_CR11","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/cns.13904","volume":"28","author":"J Ding","year":"2022","unstructured":"Ding J, Jiang X, Cai Y, Pan S, Deng Y et al (2022) Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study. CNS Neurosci Ther 28:1613\u20131623. https:\/\/doi.org\/10.1111\/cns.13904","journal-title":"CNS Neurosci Ther"},{"key":"12036_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030962","author":"F Sun","year":"2023","unstructured":"Sun F, Wu H, Wang Z, Wu T, Wu X et al (2023) Effectiveness and safety of belimumab in Chinese lupus patients: a multicenter real-world observational study. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11030962","journal-title":"Biomedicines"},{"key":"12036_CR13","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ et al (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:e1425\u2013e1434. https:\/\/doi.org\/10.1212\/WNL.0000000000005323","journal-title":"Neurology"},{"key":"12036_CR14","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/leu.2014.61","volume":"28","author":"M Jourdan","year":"2014","unstructured":"Jourdan M, Cren M, Robert N, Bollor\u00e9 K, Fest T et al (2014) IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia 28:1647\u20131656. https:\/\/doi.org\/10.1038\/leu.2014.61","journal-title":"Leukemia"},{"key":"12036_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221141253","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. https:\/\/doi.org\/10.1177\/09612033221141253","journal-title":"Lupus"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12036-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:16:38Z","timestamp":1704471398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["12036"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12036-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"27 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (XYFY2021-KL299). The patients gave explicit informed consent to report their clinical cases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}